Government Affairs/Life Sciences, Foley Hoag LLP, Boston, Massachusetts, USA.
Clin Pharmacol Ther. 2010 Dec;88(6):751-4. doi: 10.1038/clpt.2010.234.
The decision makers who approve or deny payment for health-care services review many new technologies. Reimbursement for companion diagnostics for expensive drugs ("personalized medicine") is already under close policy scrutiny, in line with long-standing concerns about overuse of diagnostic tests. Evaluation of diagnostic tests adds some complexities to the payer's comparative-effectiveness evaluation for drugs alone. Currently, decision-making frameworks suitable for companion diagnostics are being developed for practical application by payer policy makers.
负责审批或拒付医疗服务费用的决策者会对许多新技术进行评估。昂贵药物（“个体化药物”）的伴随诊断试剂的报销已经受到密切政策审查，这符合长期以来对过度使用诊断检测的担忧。与药物相比，诊断检测的评估给支付方的药物比较效益评估增加了一些复杂性。目前，支付方政策制定者正在开发适合伴随诊断试剂的决策框架，以便实际应用。
